SOPHiA GENETICS (SOPH) Osake Kurssi
SOPHiA GENETICS Kurssi
Viimeisten 6 vuoden aikana SOPHiA GENETICSn liikevaihto kasvoi 20,0 % vuodessa ja ylsi 72,72 M USD:een. SOPHiA GENETICSn nettomarginaali −108,6 % on noussut verrattuna −185,2 %:iin muutama vuosi sitten. SOPHiA GENETICSn 12 kuukauden konsensustavoitehinta on 11,50 USD, noin yli kurssia 68,3 %. 11 analyytikosta 10 suosittaa ostoa — kokonaiskonsensus on Osta.
SOPHiA GENETICS osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
SOPHiA GENETICS liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset SOPHiA GENETICS -osakkeesta
The business model of Sophia Genetics SA is focused on providing advanced data analytics solutions for genomic testing. Sophia Genetics offers a cloud-based platform that utilizes artificial intelligence (AI) and machine learning algorithms to analyze genetic data and assist healthcare professionals in making more accurate diagnoses and treatment decisions. They collaborate with a wide network of medical laboratories worldwide, helping to improve the accessibility and efficiency of genomic testing. With their comprehensive suite of solutions, Sophia Genetics aims to drive precision medicine and enable personalized healthcare on a global scale.
Sophia Genetics SA is primarily active in the healthcare and biotechnology industries.
The main competitors of Sophia Genetics SA in the market include companies such as Illumina, Thermo Fisher Scientific, and Qiagen.
Sophia Genetics SA is a leading healthtech company specializing in data-driven medicine and advanced genomic analysis. Founded in 2011 by Jurgi Camblong and Pierre Hutter, the company has since revolutionized the field of clinical genomics. Sophia Genetics uses artificial intelligence and machine learning to analyze patients' genomic data, providing accurate diagnoses and personalized treatment recommendations. With offices in Switzerland, the United States, and other countries, Sophia Genetics has collaborated with over 1,000 hospitals worldwide, improving patient care and outcomes. This company has quickly gained global recognition for its innovative solutions, which harness the power of genomics to transform healthcare.
Some significant milestones achieved by Sophia Genetics SA include securing a strategic partnership with Illumina, a global leader in DNA sequencing and array-based technologies. The company also expanded its genomic analysis platform to cover a wide range of genetic diseases, enabling more efficient and accurate diagnoses. Sophia Genetics SA has gained recognition by joining forces with renowned academic institutions and leading hospitals worldwide. Additionally, the company has received various prestigious awards, including being named a Global Cleantech prestigious 100 company. These achievements showcase Sophia Genetics SA's commitment to advancing genomic medicine and revolutionizing healthcare through innovative solutions and collaborations.
Sophia Genetics SA is primarily present in various countries and regions across the globe. Some of the key areas where the company has a significant presence include Europe, North America, Asia-Pacific, and the Middle East. With their advanced genomic data analysis solutions and services, Sophia Genetics SA has gained recognition and partnerships with renowned institutions, hospitals, and research centers in numerous countries. Their presence spans across multiple continents, making them a global leader in the field of genomics and personalized medicine.
Sophia Genetics SA represents values of innovation, collaboration, and integrity in the field of genetic testing and analysis. The company believes in harnessing the power of data and technology to revolutionize healthcare delivery. Sophia Genetics SA's corporate philosophy is centered around democratizing genomics, making it accessible and affordable for all. By providing advanced solutions for genomic data analysis, the company aims to empower healthcare professionals in making informed decisions and improving patient outcomes. Sophia Genetics SA's commitment to accuracy, transparency, and continuous research drives its mission to transform the future of personalized medicine.
Analyytikot asettavat tällä hetkellä SOPHiA GENETICS-osakkeelle keskimääräisen tavoitehinnan 11,50 USD (mediaani: 11,50 USD), mikä merkitsee +68,3 % viimeisimpään hintaan verrattuna. Konsensus perustuu 11 analyytikkoarvioon.
11 analyytikkoa arvioi tällä hetkellä SOPHiA GENETICS-osaketta: 10 suosittaa ostoa, 1 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat SOPHiA GENETICS-yhtiöltä 95,40 M USD liikevaihtoa ja −0,91 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla SOPHiA GENETICS-osake noteerataan hintaan 6,13 EUR (6,84 USD).
SOPHiA GENETICS-osake (SOPH) on listattuna 2 pörssissä, muun muassa: NASDAQ (SOPH), Frankfurt (90B.F).
Sophia Genetics SA is a Swiss company that specializes in providing advanced solutions for the analysis of genomic data. They work closely with leading hospitals and research institutions as part of their mission to improve healthcare. The business model of Sophia Genetics includes providing bioinformatics solutions to hospitals and clinics, using artificial intelligence and machine learning to improve clinical genomics and help doctors and researchers identify genetic anomalies and mutations faster and more accurately. Another important area of Sophia Genetics' business is collaboration with pharmaceutical companies in the development of personalized medicines. They collect and analyze data from patients with specific diseases to develop and test personalized treatment options. These partnerships also provide Sophia Genetics with access to large-scale studies and databases that provide more information about certain diseases. Sophia Genetics also offers a range of specialized products, including SOPHiA DDM, SOPHiA GENETICS Clinical Insights, SOPHiA AI Platform, and SOPHiA Solid Tumor Solution. SOPHiA DDM is a cloud-based platform that allows medical professionals and researchers to analyze genomic data and draw conclusions about diseases and treatment options. SOPHiA GENETICS Clinical Insights provides real-time interpretation support for the diagnosis and treatment of patients. SOPHiA AI Platform is an AI-based solution that helps interpret genomic data. SOPHiA Solid Tumor Solution is a diagnostic tool specialized in identifying genetic anomalies in tumor tissue samples. Sophia Genetics' technology is also applicable to a variety of industries, such as the agricultural industry. They collaborate with global biotechnology companies to develop new plant varieties and optimize agricultural processes. Over the years, Sophia Genetics has built numerous partnerships and collaborations with leading institutions and companies in the healthcare and bioinformatics industry. Their customers include hospitals, diagnostic laboratories, biorepositories, and pharmaceutical companies in Europe, North America, the Middle East, Africa, and Asia. In summary, the business model of Sophia Genetics SA is based on providing innovative bioinformatics solutions. They collaborate with leading institutions in the healthcare and bioinformatics industry and offer specialized products to improve the diagnosis and treatment of patients and develop personalized medicines. Their focus on collaboration with pharmaceutical companies and medical institutions, as well as the applicability of their technology to other industries, has made Sophia Genetics a key player in the journey towards personalized medicine.
odotettu liikevaihto SOPHiA GENETICS on 95,40 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto SOPHiA GENETICS on −62,15 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
SOPHiA GENETICS:n hinta-voitto-suhde (P/E) on tällä hetkellä −7,50. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan SOPHiA GENETICS-osakkeen arvostusta.
SOPHiA GENETICS:n hinta-myynti-suhde (P/S) on tällä hetkellä 4,89. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii SOPHiA GENETICS-osakkeen arvostuskennuslukuna.
SOPHiA GENETICS:n Eulpool-laatuscore on 4/10.
SOPHiA GENETICS:n ISIN on CH1125843347. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
SOPHiA GENETICS:n WKN on A3CVT8. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
SOPHiA GENETICS:n ticker on SOPH. Tämä pörssinoteeraus käytetään SOPHiA GENETICS-osakkeiden kauppaan pörssissä.
SOPHiA GENETICS osake
SOPHiA GENETICS vertaisryhmä
SOPHiA GENETICS Ticker
SOPHiA GENETICS FIGI
Kaikki tunnusluvut ja syvällinen analyysi SOPHiA GENETICS:sta
Meidän osakeanalyysimme SOPHiA GENETICS-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut SOPHiA GENETICS:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: